Table 2.
Summary of Study Results for All Subjects
All subjects | Symptom duration |
SMI312+ dystrophic neurites |
GFAP+ astrocytes |
IBA1+ microglia |
CD68+ microglia |
|||||
---|---|---|---|---|---|---|---|---|---|---|
Kendall τ | P | Kendall τ | P | Kendall τ | P | Kendall τ | P | Kendall τ | P | |
Symptom duration | 0.34∗ | 0.001∗ | 0.30∗ | 0.003∗ | 0.045 | 0.655 | 0.48∗ | <0.0001∗ | ||
SMI312+ dystrophic neurites | 0.34∗ | 0.001∗ | −0.028 | 0.735 | 0.006 | 0.943 | 0.008 | 0.929 | ||
GFAP+ astrocytes | 0.30∗ | 0.003∗ | −0.028 | 0.735 | −0.137 | 0.064 | −0.014 | 0.849 | ||
IBA1+ microglia | 0.045 | 0.655 | 0.006 | 0.849 | −0.137 | 0.064 | 0.109 | 0.151 | ||
CD68+ microglia | 0.48∗ | <0.0001∗ | 0.008 | 0.929 | −0.014 | 0.849 | 0.109 | 0.151 |
Depicted are correlations between the Kolmogorov-Smirnov distances of pairs of distribution histograms of a given plaque-associated feature and the difference in symptom duration of that pair of subjects, and the correlations between the median values of the distribution histograms for a given pair of plaque-associated features (ie, GFAP+ astrocytes versus CD68+ microglia). Data refer to all subjects, that is, 40 AD and 9 CTRL subjects (8 for SMI312+ dystrophic neurites).
AD, Alzheimer disease; CTRL, control.
Statistically significant results.